Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982359 | 0.85 | POLB (0.44) | MEN1KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL3034809 | 0.84 | HPGD (0.49) | MAPK1MEN1KMT2AHPGDPOLB | |
| SCHEMBL3034527 | 0.82 | HPGD (0.55) | MAPK1HPGDPOLBALDH1A1PYGL | |
| SCHEMBL743868 | 0.81 | LMNA (0.41) | KMT2AHPGDPOLBALDH1A1GAA | |
| SCHEMBL30760510 | 0.78 | KMT2A (0.68) | MAPK1MEN1KMT2AHPGDPOLB | |
| SCHEMBL6126432 | 0.77 | CHRM1 (0.37) | — | |
| SCHEMBL1355068 | 0.76 | ALDH1A1 (0.41) | KMT2AHPGDPOLBALDH1A1GAA | |
| SCHEMBL744223 | 0.76 | GAA (0.56) | MEN1KMT2AHPGDPOLBALDH1A1 | |
| SCHEMBL7967927 | 0.76 | NPC1 (0.50) | MAPK1MEN1KMT2AHPGDPOLB | |
| SCHEMBL12124297 | 0.75 | MEN1 (0.56) | MAPK1MEN1KMT2AHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | MAPK1 63/4885MEN1 829/4885KMT2A 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.